{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"6.1","value":"3.6"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"3.4","value":"2.2"}]}],"title":"Isolated CNS Relapse"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"3.0","value":"1.4"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"4.4","value":"3.0"}]}],"title":"Isolated Bone Marrow Relapse"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"2.9","value":"1.3"},{"groupId":"OG001","lowerLimit":"0.8","upperLimit":"2.8","value":"1.8"}]}],"title":"Combined Bone Marrow Relapse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"634"}],"units":"Participants"}],"description":"Cumulative incidence of isolated CNS relapse adjusting for competing risks using the method of: Gray R, A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1141:1154, 1988","dispersionType":"95% Confidence Interval","groups":[{"description":"T-ALL patients on AALL1231 who did not receive prophylactic cranial radiation and did not receive bortezomib: Intermediate Risk T-ALL (exclude CNS3) and SR T-ALL (exclude those who met AALL0434 Low Risk definition).","id":"OG000","title":"AALL1231 T-ALL Patients"},{"description":"T-ALL patients on AALL0434 \\[NCT00408005\\] who received prophylactic cranial radiation and did not receive nelarabine (exclude Low Risk, CNS3, M3 Day 29, and EOC MRD \\>0.1%);","id":"OG001","title":"AALL0434 T-ALL Patients"}],"paramType":"NUMBER","populationDescription":"T-ALL patients on AALL1231 who did not receive CRT or bortezomib: IR (exclude CNS3) and SR T-ALL (exclude those who met AALL0434 \\[NCT00408005\\] Low Risk definition). T-ALL on AALL0434 \\[NCT00408005\\](who received CRT, no nelarabine) excluding Low Risk, CNS3, M3 Day 29, and EOC MRD \\>0.1%","reportingStatus":"POSTED","timeFrame":"3 years","title":"Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}